Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Garmezy on Future Therapeutic Prospects for RCC

May 15th 2024

Meta: Benjamin Garmezy, MD discusses future therapeutic prospects for patients with variant renal cell carcinoma (RCC)

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC

May 11th 2024

Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.

Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC

May 10th 2024

A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.

Dr Beckermann on Targeting TREM2 in the Treatment of ccRCC

May 7th 2024

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

May 6th 2024

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 6th 2024

The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.

Dr Wang on the Role of Active Surveillance in Patients With Renal Masses

May 4th 2024

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

Dr Merchán on the Future Treatment of Advanced RCC

May 3rd 2024

Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

April 29th 2024

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

Dr Gopal on Future Research Directions in Non-ccRCC

April 26th 2024

Nikhil A. Gopal, MD, discusses future research directions for the treatment of various renal cell carcinoma histologies.

Dr Srour on the Ongoing Investigation of CAR T-Cell Therapy in Advanced RCC

April 23rd 2024

Samer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

Dr Tannir on Unmet Needs in the Treatment of Rare Kidney Tumors

April 18th 2024

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

Dr Srour on Toxicities Associated With CAR T-Cell Therapy in RCC and Other Solid Tumors

April 17th 2024

Samer A. Srour, MB ChB, MS, discusses toxicities associated with CTX130 in advanced clear cell renal cell carcinoma.

Dr Srour on the Utility of CTX130 in RCC

April 16th 2024

Samer A. Srour, MB ChB, MS, discusses the utility of the CAR T-cell therapy CTX130 and unmet needs in advanced clear cell renal cell carcinoma.

Dr Grivas on Frontline Treatment Options in Metastatic RCC

April 12th 2024

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

April 12th 2024

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

TKI Monotherapy Data in Non–Clear Cell RCC

April 12th 2024

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.